Compare LGVN & JZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGVN | JZ |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 34.6M |
| IPO Year | 2021 | 2021 |
| Metric | LGVN | JZ |
|---|---|---|
| Price | $0.80 | $0.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 379.1K | ★ 4.8M |
| Earning Date | 05-08-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $709,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $0.25 |
| 52 Week High | $1.80 | $3.35 |
| Indicator | LGVN | JZ |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 44.54 |
| Support Level | $0.74 | N/A |
| Resistance Level | $0.86 | $1.29 |
| Average True Range (ATR) | 0.07 | 0.34 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 78.25 | 1.10 |
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
Jianzhi Education Technology Group Co Ltd engages in developing educational content to fulfill the massive demand for high-quality, professional development training resources in China. The company and its subsidiaries VIE and VIEs generate subscription revenue through selling subscriptions to online learning platforms, higher education institutions, and other institutional customers under a B2B2C model mainly through the platform of Sentu Academy; offering subscriptions concerning educational content in mobile video packages directly to end users under a B2C model through the platforms such as Fish Learning or Light Class, etc. It has single operating segment: Educational content services and other services and IT-related solution services.